Tirzepatide provides a unique approach to combating these conditions by not only helping to control blood sugar levels but also by addressing key risk factors associated with heart disease
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
Pharmacological GLP-1RA Action Key Mechanistic Distinctions A comprehensive review published in Cell Metabolism reviewed circuits engaged by endogenous versus pharmacological GLP-1 action, highlighting key GLP-1R-positive cell types and pathways transducing metabolic and non-glycaemic GLP-1 signals
While compounding pharmacies do have their place in medicine, they certainly werent intended to serve as a gray market offshoot for FDA-approved drugsdrugs that have to undergo a lengthy process to vet their safety and effectiveness
